London, October 1st, 2024 - Pangea Bio, a company developing transformative medicines for neurological and neuropsychiatric disorders, today announced that leading ethnopharmacologist Fabien Schultz has joined their team as an independent contractor.

Fabien is a distinguished ethnopharmacologist known for his groundbreaking research in natural product discovery and traditional medicine. His innovative work has led to the identification of several bioactive compounds with therapeutic potential, bridging the gap between indigenous knowledge and modern science. Fabien has published numerous influential papers, contributed to key advancements in pharmacological applications, and collaborated with diverse communities to promote sustainable practices in ethnobotany. His commitment to advancing the field has earned him recognition as a leader in ethnopharmacology. He has earned numerous accolades and awards.

Fabien is currently conducting ethnopharmacological research in five countries and has great expertise in studying the traditional medicinal application of natural remedies in indigenous communities. His innovative approach to ethnopharmacology, where the location and research analysis is brought full circle by transferring the results from all stages of a project back to the indigenous people who helped me to begin the process aligns perfectly with Pangea’s commitment to the Nagoya Protocol.

At Pangea, he will collaborate with the AI team to advance discovery programs, leverage ethnopharmacology for plant selection, and grow partnerships to access more biodiversity.